MRK Investors Have the Opportunity to Lead the Merck Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Merck & Co., Inc. due to allegations of false and misleading statements regarding the company's revenue expectations from Gardasil sales, particularly in China, which led to inflated stock prices and subsequent losses for investors [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Merck between February 3, 2022, and February 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Merck, with a deadline of April 14, 2025, for investors to seek the role of lead plaintiff [3][8]. - The complaint alleges that Merck and its executives violated federal securities laws by making false statements about Gardasil's expected revenue of $11 billion by 2030 and failing to disclose the true demand situation in China [5]. Group 2: Financial Performance and Market Reaction - On February 4, 2025, Merck reported a 3% decline in Gardasil/Gardasil 9 sales, totaling $8.6 billion, and announced a temporary pause in shipments to China [6]. - Following this announcement, Merck's stock price dropped by $9.05 per share, or 9.1%, closing at $90.74 per share [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].